Influenza Treatment Global Market Report 2024 Global Market Analysis, Trends, Growth, Research And Forecast 2033

The new report published by The Business Research Company, titled "Influenza Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the influenza treatment market size has grown steadily in recent years. It will grow from $6.34 billion in 2023 to $6.60 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%. The influenza treatment market size is expected to see steady growth in the next few years. It will grow to $7.83 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample_request?id=15832&type=smp

Rising Prevalence Of Contagious Respiratory Illnesses Drives Influenza Treatment Market Growth
The increased prevalence of contagious respiratory illnesses is expected to propel the influenza treatment market going forward. Contagious respiratory illness refers to an infectious disease, such as influenza, measles, or respiratory syncytial virus (RSV) infections, transmitted through contact with an infected individual or their bodily fluids, contaminated surfaces, or objects. Factors driving the growth of contagious respiratory illness include higher population densities, inadequate healthcare infrastructure, misuse of antibiotics, and international travel facilitation. Influenza treatment consists of antiviral drugs and vaccinations that are used to treat various contagious respiratory illnesses such as flu, COVID-19, and other respiratory viruses. For instance, in September 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, the rate of hospitalizations linked to RSV (Respiratory Syncytial Virus) surged from 2 hospitalizations per 100,000 people during the week ending August 5, 2023, to 7 hospitalizations per 100,000 individuals by the week concluding on August 19, 2023. Therefore, the increased prevalence of contagious respiratory illnesses is driving the growth of the influenza treatment market.

Companies Expand Influenza Treatment Options With Single-Dose Oral Medicines
Major companies operating in the influenza treatment market are focusing on expanding their product portfolio by adding innovative solutions, such as single-dose oral medicine for influenza treatment, to enhance patient compliance, improve treatment outcomes, and capture a larger market share. A single-dose oral medicine refers to a medication designed to treat influenza (flu) with just one oral dose, simplifying the treatment regimen. For instance, in August 2022, Genentech Inc., a US-based biotechnology company, announced the U.S. Food and Drug Administration (FDA) approval for Xofluza (Baloxavir Marboxil). Xofluza is the first and only single-dose oral medicine that offers a convenient and efficient solution for managing acute uncomplicated influenza in children aged five to less than 12 years who have been symptomatic for no more than 48 hours and other respiratory viruses.

The influenza treatment market covered in this report is segmented -

1) By Product Type: Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, Other Products
2) By Route Of Administration: Oral, Other Routes Of Administration
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=15832&type=discount

Major companies operating in the influenza treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc , Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Fujifilm Holdings Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited., Chugai Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Cipla Ltd, Dr. Reddy's Laboratories Ltd., Lupin Limited, NATCO Pharma Limited, BioCryst Pharmaceuticals Inc., NanoViricides Inc.

Contents of the report:
1. Executive Summary
2. Influenza Treatment Market Report Structure
3. Influenza Treatment Market Trends And Strategies
4. Influenza Treatment Market - Macro Economic Scenario
5. Influenza Treatment Market Size And Growth
…..
27. Influenza Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.